cagrilintide semaglutide combination phase 3 2024 Novo Nordisk has officially filed for FDA approval of CagriSema Novo's Phase 3 CagriSema results

According to the UK Summary of Product Characteristics (SmPC), there is no specific contraindication for using Mounjaro in patients with Graves' disease, but careful consideration of individual circumstances is necessary

These variations are typically temporary and often resolve within 3-6 months as your body adapts to its new weight and hormone balance stabilizes

Fully managed staffing with one of the nations largest and highest rated telehealth clinician networks

In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)